Evidence That Patients With Single Versus Recurrent Depressive Episodes Are Differentially Sensitive to Treatment Discontinuation: A Meta-Analysis of Placebo-Controlled Randomized Trials
The DOI matches its Crossref record, with a small difference in title or year; 66 of the 66 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Antidepressants are effective in the prevention of relapse after remission from an acute depressive episode. It is unclear, however, to what degree duration of the continuation phase, level of abruptness of antidepressant discontinuation, or the number of previous episodes moderate the prophylactic effect of antidepressants. DATA SOURCES: Searches were conducted to identify all published randomized, placebo-controlled, double-blind clinical trials available for review by May 2007 on the efficacy of continuation or maintenance treatment of major depressive disorder with either selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs) that included patients entering a maintenance phase after achieving remission from the acute phase. The MEDLINE and EMBASE databases were searched using the terms depression, antidepressants, discontinuation, and maintenance treatment; this was followed by reference checks of articles thus identified. In addition, the Cochrane Library was also searched using the same terms. Some authors of the identified papers were contacted for specific data. DATA SYNTHESIS: Data were collected from 30 trials with 4890 participating patients. The overall reduction of relapse risk in the maintenance phase was highly significant for both SSRIs (OR = 0.24, 95% CI = 0.20 to 0.29) and TCAs (OR = 0.29, 95% CI = 0.23 to 0.38) over 1 year of follow-up of maintenance treatment. The prophylactic effect appeared to be constant over the length of the continuation phase. Recurrent episode patients experienced less protection from antidepressants over the maintenance phase (OR = 0.37, 95% CI = 0.31 to 0.44) than single episode patients (OR = 0.12, 95% CI = 0.06 to 0.26). CONCLUSIONS: Antidepressants robustly reduce relapse risk in the maintenance phase, regardless of a number of clinical and pharmacologic factors. There is evidence, however, that with increasing number of episodes, patients develop a relative resistance against the prophylactic properties of antidepressant medication.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Kaymaz et al. (2008) came to the diametrically opposed conclusion, finding that an increasing number of prior episodes instead reduced the prophylactic effect of antidepressants.”
From Predicting relapse after antidepressant withdrawal – a systematic review (2017) · cites this paper as Kaymaz et al. 2008
In the citing paper
“Antidepressant medications (ADM) have proven utility not only in treating acute episodes of depression, but also in reducing the risk of relapse (Geddes et al. 2003; Kaymaz et al. 2008; Glue et al. 2010; Sim et al. 2015).”
From Predicting relapse after antidepressant withdrawal – a systematic review (2017) · cites this paper as Kaymaz et al. 2008
In the citing paper
“Using a meta-regression approach, they later found that the odds ratio for relapse after discontinuation compared with continuation in first-episode patients was 0.12, while it was 0.31 in patients in their second or more episodes.”
From Predicting relapse after antidepressant withdrawal – a systematic review (2017) · cites this paper as Kaymaz et al. 2008
In the citing paper
“Several meta-analyses (Viguera et al. 1998; Geddes et al. 2003; Kaymaz et al. 2008; Glue et al. 2010; Andrews et al. 2011) have, however, examined it, with none finding a significant effect.”
From Predicting relapse after antidepressant withdrawal – a systematic review (2017) · cites this paper as Kaymaz et al. 2008
In the citing paper
“Several systematic reviews of studies have shown a higher rate of relapse among patients who discontinue antidepressant therapy than among those who continue to receive such therapy”
From Maintenance or Discontinuation of Antidepressants in Primary Care (2021) · cites this paper as [7]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Funnel plots for detecting bias in meta-analysis
Sterne, J. A. C., & Egger, M. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00377-8 · Cited by 3,779 · cited 1×
“Another limitation is that our results may be subject to publication bias as negative trials are more likely to remain unpublished.(72) This is a general limitation of any conclusion based on perusal of the literature.”
BackgroundFrank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 1×
“In 1988, the MacArthur Foundation Research Network on the Psychobiology of Depression convened a task force to examine the ways in which change points in the course of depressive illness until that time had been described and the extent to which inconsistencies in these descriptions might hinder research on this disor…”
BackgroundThree-Year Outcomes for Maintenance Therapies in Recurrent Depression
Frank, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240013002 · Cited by 1,297 · cited 1×
“Number of Previous Depressive Episodes A history of severe and frequently recurring depressive episodes is considered to be a plausible clinical predictor of increased risk of relapse or recurrences after discontinuation of the antidepressant.(22,26,55) Regarding the second question (of whether treatment should be con…”
ResultRelapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 1×
“In a 2003 meta-analysis of 31 randomized trials (4410 participants), Geddes et al.(6) showed that continuing antidepressant therapy consistently reduced the risk of relapse and recurrence by 70% compared with continuation with placebo, and this seemed to be similar for all classes of antidepressants.”
BackgroundReynolds III, C. F., Frank, E., Perel, J. M., Imber, S. D., Cornes, C., Miller, M. D., Mazumdar, S., Houck, P. R., Dew, M. A., Stack, J. A., et al. (1999) · JAMA · doi:10.1001/jama.281.1.39 · Cited by 659
Prien, R. F. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220086014 · Cited by 565
Spijker, J., De Graaf, R., Bijl, R. V., Beekman, A. T. F., Ormel, J., & Nolen, W. A. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.181.3.208 · Cited by 514 · cited 1×
“tients experience a chronic course, and 75% to 80% of patients experience recurrent episodes.(1,2) Therefore, treatment should focus not only on improving symptoms of the acute episode but also on the prevention of relapse (return of symptoms of the index episode) and recurrence (the development of a subsequent episod…”
BackgroundTreatment of Depression by Drugs and Psychotherapy
KLERMAN, G. L., DIMASCIO, A., WEISSMAN, M., PRUSOFF, B., & PAYKEL, E. S. (1974) · American Journal of Psychiatry · doi:10.1176/ajp.131.2.186 · Cited by 500
Executive Dysfunction and Long-term Outcomes of Geriatric Depression
Alexopoulos, G. S., Meyers, B. S., Young, R. C., Kalayam, B., Kakuma, T., Gabrielle, M., Sirey, J. A., & Hull, J. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.285 · Cited by 486
Angst, J. (1992) · Psychopharmacology · doi:10.1007/bf02246240 · Cited by 409 · cited 1×
“tients experience a chronic course, and 75% to 80% of patients experience recurrent episodes.(1,2) Therefore, treatment should focus not only on improving symptoms of the acute episode but also on the prevention of relapse (return of symptoms of the index episode) and recurrence (the development of a subsequent episod…”
Background
Cited by
Items 101–141 of 141
Peñaranda, A. P. B., Valencia, J. G., Guarín, M. R., Borrero, Á. E. A., Castro, S., Bradford, A. M. D. L. H., Riveros, P. M., Jaramillo, L. E., Brito, E., Acosta, C. A. P., et al. (2012) · Revista Colombiana de Psiquiatría · doi:10.1016/s0034-7450(14)60045-7 · Cited by 9
Hoyer, C., Sartorius, A., Lecourtier, L., Kiening, K. L., Meyer‐Lindenberg, A., & Gass, P. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.07.014 · Cited by 6
“[37,92].”
Wu, R., Kemp, D. E., Sajatovic, M., Zhao, J., Calabrese, J. R., & Gao, K. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.11.013 · Cited by 6
An update on pharmacotherapy for recurrent depression in 2022
Belge, J.-B., Sabbe, A. C. F., & Sabbe, B. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2223962 · Cited by 7
Healthcare Providers' Perspectives on Antidepressant Discontinuation: A Focus Group Study
Bouarfa, S., Göttgens, W., Ligthart, S. A., Maarsingh, O. R., Vinkers, C. H., Ruhé, H. G., Bet, P. M., & Hugtenburg, J. G. (2025) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70051 · Cited by 5
“On the other hand, maintenance AD therapy lowers recurrence rates of depression or anxiety [10–12].”
Discontinuation of long-term antidepressant use for depressive and anxiety disorders in adults
Leeuwen, E. V., van Driel, M., Sutter, A. I. D., Anderson, K., Robertson, L., & Christiaens, T. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495 · Cited by 6
Høstmælingen, A., Ulvenes, P., Nissen‐Lie, H. A., Eielsen, M., & Wampold, B. E. (2022) · Journal of Counseling Psychology · doi:10.1037/cou0000572 · Cited by 6
Bockting, C., Breedvelt, J., & Brouwer, M. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818697-8.00224-7 · Cited by 6
Wagner, G. J., Ghosh‐Dastidar, B., Faherty, L. J., Beyeza‐Kashesya, J., Nakku, J. E. M., Nabitaka, L. K., Akena, D. H., Nakigudde, J., Ngo, V. K., McBain, R. K., et al. (2023) · Women s Reproductive Health · doi:10.1080/23293691.2023.2255587 · Cited by 5
Gómez–Restrepo, C., Peñaranda, A. P. B., Valencia, J. G., Guarín, M. R., Narváez, E. B., Jaramillo, L. E., Acosta, C. A. P., Pedraza, R. S., & Castro, S. (2012) · Revista Colombiana de Psiquiatría · doi:10.1016/s0034-7450(14)60044-5 · Cited by 6
Fava, G. A. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001468 · Cited by 4
Bezuidenhout, J. (2015) · South African Family Practice · doi:10.4102/safp.v57i4.4269 · Cited by 4
Weinig overbehandeling met antidepressiva
Piek, E., van der Meer, K., Nolen, W. A., Hoogendijk, W. J. G., & Penninx, B. W. J. H. (2012) · Huisarts en Wetenschap · doi:10.1007/s12445-012-0032-8 · Cited by 4
Risk factors and prevention of recurrent dynamics of depression
Veltishchev, D. Y., Kovalevskaya, O. B., & Seravina, O. (2017) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro201711761120-125 · Cited by 3
Stopping antidepressants following depression
Pringsheim, T. M., Kelly, M. A., & Barbui, C. (2016) · BMJ · doi:10.1136/bmj.i220 · Cited by 3
Jacobsen, P. L., Zhong, W., Xu, R., & Nomikos, G. G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.090 · Cited by 3
Berwian, I. M., Wenzel, J. G., Kuehn, L., Schnuerer, I., Seifritz, E., Stephan, K. E., Walter, H., & Huys, Q. J. M. (2020) · Biological Psychiatry · doi:10.1101/2020.01.28.922500 · Cited by 3
Berwian, I. M., Tröndle, M., Miquel, C. D., Ziogas, A., Stefanics, G., Walter, H., Stephan, K. E., & Huys, Q. J. M. (2023) · doi:10.1101/2023.07.05.547831 · Cited by 2
Riiser, S., Smith‐Sivertsen, T., Baste, V., Haukenes, I., Hetlevik, Ø., & Ruths, S. (2025) · BMC Family Practice · doi:10.1186/s12875-025-02825-x · Cited by 2
“Although several meta-analyses show robust evidence on the protective effect of antidepressants in preventing relapse and recurrence of depression [8, 9, 11], some trials have shown only a modest protective effect [15].”
Medication-Induced Movement Disorders and Other Adverse Effects of Medication
(2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890425787.medication_induced_movement_disorders · Cited by 2
Fried, E. I. (2014) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-14966 · Cited by 3
Bockting, C. (2015) · Utrecht University Repository (Utrecht University) · Cited by 2
Argungu, Z. M., Alhaiti, A., & Jibreel, E. A. (2025) · International Journal of Social Psychiatry · doi:10.1177/00207640251405457 · Cited by 1
“The most common strategy to prevent relapse/recurrence after a depressive episode is maintenance antidepressant medication (mADM), which has been found more effective than a placebo (Kaymaz et al., 2008).”
Three Decades of SSRI/SNRI Withdrawal Research: A Bibliometric and Science-Mapping Study
Akça, E. (2026) · The European Research Journal · doi:10.18621/eurj.1825803 · Cited by 1
Elad, D., Story, G. W., Berwian, I. M., Stephan, K. E., Walter, H., & Huys, Q. J. M. (2026) · Molecular Psychiatry · doi:10.1038/s41380-025-03402-5 · Cited by 3
“Where replications do exist, these sometimes reach con fl icting conclusions, for example regarding the effect of the number of previous episodes on future relapse risk [6, 19].”
Moriarty, A. S., Robertson, L., Mughal, F., Cook, N., Gilbody, S. M., McMillan, D., Chew-Graham, C. A., Ali, S., Hetrick, S. E., Churchill, R. C., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014832 · Cited by 3
“Absolute benefits from ADMs are greater for those at higher initial risk of relapserecurrence (Geddes 2003), and the eGect may decrease aKer a number of depressive episodes, as patients appear to develop resistance to their prophylactic properties (Kaymaz 2008).”
BackgroundBosaipo, N. B. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2016.tde-26082016-153726 · Cited by 4
Cognitive-Behavioural Therapy Combined with Antidepressants for Major Depressive Disorder
Maneeton, N. (2012) · InTech eBooks · doi:10.5772/30340
“However, the larger number of depressive episodes may suggest a relative resistance against the prophylactic treatment from antidepressant (Kaymaz et al., 2008).”
Studies of the affective and developmental domains of psychopathology in psychosis
Kaymaz, N. (2011) · Research Publications (Maastricht University) · doi:10.26481/dis.20110622nk
Self-citationPasterkiewicz, U. B. (2017) · UWSpace (University of Waterloo) · Cited by 1
Relapse prevention strategies for recurrent depression
Klein, N. S. (2019) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Joel Paris, M. D. (2010) · Wiley eBooks · doi:10.1002/9780470666630.refs
Psychopharmacological Treatment
Sant, S. V. (2016) · Evidence-based practices in behavioral health · doi:10.1007/978-3-319-40537-7_7
Epstein-Lubow, G. P., & Kohn, R. (2015) · Wiley eBooks · doi:10.1002/9781118625392.wbecp153
Fava, G. A. (2018) · Elsevier eBooks · doi:10.1016/b978-2-294-76050-1.00014-3
Transcranial magnetic stimulation for treatment-resistant depression
Batail, J.-M. V., Narita, Z. C., Coetzee, J. P., Brown, J. C., Nejad, R., Stimpson, K. H., Phillips, A., Cole, E. J., Sahlem, G. L., & Williams, N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00017-7 · Cited by 1
Comprendre la physiopathologie des syndromes de sevrage
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00004-2
Wb, Z., Zhang, H., Shi, G., Chen, R., Yiming, S., Wang, W., Guo, L., Liu, Y., Liao, Y., Hao, J., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.121116
Lin, K., Hasegawa, K., Rapelli, V. R., Yang, J., Parsey, R. V., & DeLorenzo, C. (2026) · Scientific Reports · doi:10.1038/s41598-026-43078-7
“Importantly, consistent with other studies 98,99 , there was significant variability in intervention response across the cohort (for both treatment and placebo, see standard deviation in percent change in the Hamilton Depression Rating Scale, Table 1).”
Mood disruption in heroin abstinence : mechanisms and gene discovery
Ayrancı, G. (2015) · theses.fr (ABES) · doi:10.70675/a956874cz8192z4eb4zb9dez3ceb46a28053
Metadata
- Authors
- Kaymaz, N., van Os, J., Loonen, A. J. M., & Nolan, W. A.
- Affiliations
- Maastricht University (NL)
- ORCID
- Loonen, Anton J. M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2008-09-30
- Volume
- 69
- Issue
- 9
- Pages
- 1423-1436
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2118822483
- Cited by
- 135
- References
- 65
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 2 · 2021: 13 · 2020: 9 · 2019: 10 · 2018: 3 · 2017: 7 · 2016: 15 · 2015: 10 · 2014: 7 · 2013: 7 · 2012: 11
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- major depressive disorder, relapse prevention, antidepressant discontinuation, recurrent depression, selective serotonin reuptake inhibitors, tricyclic antidepressants, preventive effect, treatment resistance
- MeSH terms
- Acute Disease, Antidepressive Agents, Tricyclic, Major Depressive Disorder, Double-Blind Method, Drug Resistance, Humans, Long-Term Care, Recurrence, Substance Withdrawal Syndrome, Randomized Controlled Trials as Topic, Selective Serotonin Reuptake Inhibitors, Retreatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.